登录    
  
首页 > 期刊论文 > 论文摘要
扩增阻滞突变系统法检测非小细胞肺癌微小标本表皮生长因子受体突变
         
Detection of epidermal growth factor receptor mutations in small specimens of non-small cell lung cancer by amplification refractory mutation system

摘    要
目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)微小标本代替大体标本用于扩增阻滞突变系统(amplification refractory mutation system,ARMS)法检测表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变的可行性。方法:181例NSCLC标本纳入本研究,包括157例微小标本(分别为CT引导下经皮肺穿刺活检标本、支气管内超声引导下针吸活检标本、淋巴结活检标本、支气管镜活检标本和胸腔积液)和24例大体标本。采用QIAGEN DNA提取试剂盒提取标本组织DNA,然后使用AmoyDx人类EGFR基因4种突变荧光PCR检测试剂盒检测EGFR基因的突变情况,最后采用χ2检验或Fisher精确检验比较微小标本与大体标本的EGFR突变检出率。结果:181例标本中,EGFR的总突变率为39.8%(72/181);其中微小标本的EGFR突变检出率为38.9%,大体标本的EGFR突变检出率为45.8%,2者间差异无统计学意义(P=0.515)。EGFR突变率在不吸烟患者(P=0.033)和腺癌患者(P<0.001)中显著增高。结论:ARMS法检测NSCLC微小标本也能获得较高的EGFR突变检出率。对于晚期难以获得大体标本的NSCLC患者,微小标本可代替大体标本应用于临床EGFR突变检测。
标    签 癌,非小细胞肺   受体,表皮生长因子   DNA突变分析   ARMS   Carcinoma, non-small cell lung   Receptor, epidermal growth factor   DNA mutation analysis   ARMS  
 
Abstract
Objective: To explore the feasibility of the application of small specimens as alternatives of gross specimens to detect EGFR(epidermal growth factor receptor) mutation in NSCLC(non-small cell lung cancer) by ARMS(amplification refractory mutation system). Methods: Biopsy specimens from 181 cases of NSCLC were collected, in which 157 were small specimens(including specimens acquired through CT-guided percutaneous lung biopsy, endobronchial ultrasound-guided transbronchial needle aspiration, lymph node biopsy, bronchoscopic biopsy and aspiration of pleural effusion) and 24 were gross specimens. QIAGEN DNA extraction kit was used to extract DNAs from NSCLC specimens. Then AmoyDx EGFR Mutation Test Kit-a highly sensitive real-time PCR-based test was used to detect EGFR mutations. The detection rates of EGFR mutations in small specimens and gross specimens were compared by Chi-square test or Fisher's exact test. Results: The total EGFR mutation detection rate of all biopsy specimens was 39.8%(72/181). The detection rates of small specimens and gross specimens were 38.9% and 45.8%, respectively(P=0.515). Furthermore, EGFR mutation frequencies were significantly higher in non-smokers(P=0.033) and in patients with adenocarcinoma(P<0.001). Conclusion: A relatively high detection rate of EGFR mutation in NSCLC small specimens can be obtained through ARMS. For patients with advanced NSCLC whose gross specimens cannot be easily obtained, the alternative small specimens can be used in clinical EGFR mutation detection.

中图分类号 R734.2   DOI 10.3781/j.issn.1000-7431.2012.11.013

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 技术与方法

基金项目 国家自然科学基金资助项目(编号:81172101);上海市科委基础研究重点项目(编号:11JC1411300)

收稿日期 2012/7/16

修改稿日期 2012/9/5

网络出版日期

作者单位点击查看


引用该论文: REN Rui-xin,LI Jia-yu,LI Xue-fei,CHEN Xiu,REN Sheng-xiang,ZHOU Cai-cun. Detection of epidermal growth factor receptor mutations in small specimens of non-small cell lung cancer by amplification refractory mutation system[J]. Tumor, 2012, 32(11): 929~935
任睿欣,李嘉瑜,李雪飞,陈秀,任胜祥,周彩存. 扩增阻滞突变系统法检测非小细胞肺癌微小标本表皮生长因子受体突变[J]. 肿瘤, 2012, 32(11): 929~935


被引情况:


【1】姚传山,马磊,刘瑞青,李醒亚, "Ⅰ~Ⅲ期肺腺癌组织中EGFR基因突变与ERCC1和RRM1蛋白表达的关系",肿瘤 33, 258-263(2013)



论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
 
【2】SCAGLIOTTI G V, SELVAGGI G, NOVELLO S, et al. The biology of epidermal growth factor receptor in lung cancer[J]. Clin Cancer Res, 2004, 10(12 Pt 2):4227s-4232s.
 
【3】DAHABREH I J, LINARDOU H, SIANNIS F, et al. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer[J]. Clin Cancer Res, 2010, 16(1):291-303.
 
【4】GARASSINO M C, MARTELLI O, BETTINI A, et al. TAILOR:A phaseⅢtrial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR[C/OL]. 2012 Annual Oncology Meeting in Chicago, June 1-5, 2012:Lung cancer[2012-07-15]. http://www.primeoncology.org/online_education/solid_tumor/2012/chicago2012_pds/lung_cancer/slides
 
【5】XUE C, HU Z, JIANG W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China[J]. Lung Cancer, 2012, 77(2):371-375.
 
【6】PAO W, LADANYI M. Epidermal growth factor receptor mutation testing in lung cancer:searching for the ideal method[J]. Clin Cancer Res, 2007, 13(17):4954-4955.
 
【7】NEWTON C R, GRAHAM A, HEPTINSTALL L E, et al. Analysis of any point mutaion in DNA. The amplification refractory mutation system (ARMS)[J]. Nucleic Acids Res, 1989, 17(7):2503-2516.
 
【8】REN S, CHEN X, KUANG P, et al. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma[J]. Cancer, 2012 May 8[Epub ahead of print].
 
【9】REN S, KUANG P, ZHENG L, et al. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma[J]. Cell Biochem Biophys, 2012 Jun 17[Epub ahead of print].
 
【10】MOK T S, WU Y L, THONGPRASERT S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10):947-957.
 
【11】MITSUDOMI T, MORITA S, YATABE Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405):an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(2):121-128.
 
【12】ZHOU C, WU Y L, CHEN G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (OPTIMAL, CTONG-0802):a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8):735-742.
 
【13】ROSELL R, CARCERENY E, GERVAIS R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC):a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3):239-246.
 
【14】DOUILLARD J Y, SHEPHERD F A, HIRSH V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small cell lung cancer:data from the randomized phaseⅢINTEREST trial[J]. J Clin Oncol, 2010, 28(5):744-752.
 
【15】ZHU C Q, DA CUNHA SANTOS G, DING K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21[J]. J Clin Oncol, 2008, 26(26):4268-4275.
 
【16】QIN L, ZHONG W, ZHANG L, et al. Comparison of three methods for detecting epidermal growth factor receptor mutations in plasma DNA samples of Chinese patients with advanced non-small cell lung cancer[J]. Chin Med J (Engl), 2011, 124(6):887-891.
 
【17】LIU Y, LIU B, LI X Y, et al. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small cell lung cancer patients[J]. J Exp Clin Cancer Res, 2011, 30:111.
 
【18】ZHANG X, ZHAO Y, WANG M, et al. Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer[J]. Lung Cancer, 2008, 60(2):175-182.
 
【19】BAI H, MAO L, WANG H S, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages ⅢB to Ⅳ non-small cell lung cancer[J]. J Clin Oncol, 2009, 27(16):2653-2659.
 
【20】SANTIS G, ANGELL R, NICKLESS G, et al. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR[J]. PLoS One, 2011, 6(9):e25191.
 
【21】王理扬, 黄媚娟, 李伦, 等. 非小细胞肺癌组织化疗前后表皮生长因子受体基因的突变[J]. 肿瘤, 2011, 31(6):517-521.
 
【22】WU Y L, ZHONG W Z, LI L Y, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer:a meta-analysis based on updated individual patient data from six medical centers in mainland China[J]. J Thorac Oncol, 2007, 2(5):430-439.
 
【23】GAZDAR A F. Activating and resistance mutations of EGFR in non-small cell lung cancer:role in clinical response to EGFR tyrosine kinase inhibitors[J]. Oncogene, 2009, 28 (Suppl 1):S24-S31.
 
【24】KOSAKA T, YATABE Y, ENDOH H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib[J]. Clin Cancer Res, 2006, 12(19):5764-5769.
 
【25】ZHANG G C, LIN J Y, WANG Z, et al. Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients[J]. Clin Oncol (R Coll Radiol), 2007, 19(7):499-506.
 
相关信息
   标题 相关频次
 人肺腺癌细胞株A549和A549/DDP的比较蛋白质组学研究
 10
 表皮生长因子受体基因CA简单重复序列多态性与晚期小细胞肺癌患者表皮生长因子受体酪氨酸激酶抑制剂临床疗效间的关系
 8
 非小细胞肺癌患者EGFR基因突变状态影响因素的临床分析
 7
 人肺腺癌吉非替尼耐药细胞株中微小RNA的表达谱
 6
 微RNA-21与BIM蛋白在逆转肺腺癌细胞对EGFR-TKIs耐药中的相互拮抗作用
 6
 胸苷酸合酶基因变数串联重复多态性与培美曲塞治疗晚期非小细胞肺癌疗效相关性分析
 6
 GRIM-19基因对肺腺癌耐药细胞株A549/DDP药物敏感性及相关基因表达的影响
 4
 Ⅰ~Ⅲ期肺腺癌组织中EGFR基因突变与ERCC1和RRM1蛋白表达的关系
 4
 cRGD-氧化铁纳米粒的构建及应用于核磁共振成像诊断中的动物研究
 4
 DNA修复基因MMS19单核苷酸多态性与非小细胞肺癌组织学类型的关系
 4
 H2O2氧化刺激对紫杉醇耐药和敏感肺癌细胞的不同影响
 4
 Luffin-β靶向融合免疫毒素的构建、表达及对非小细胞肺癌的抑制作用
 4
 表皮生长因子受体信号通路与卵巢癌耐药细胞株SKOV3/DDP相关性的研究
 4
 单药培美曲塞二线治疗晚期非小细胞肺癌的疗效观察
 4
 厄洛替尼治疗晚期非小细胞肺癌的临床研究
 4
 非小细胞肺癌组织中血管内皮生长因子表达与树突状细胞分布的关系
 4
 高海拔地区老年非小细胞肺癌患者接受全电视胸腔镜下肺叶切除的安全性和预后分析
 4
 化疗序贯厄洛替尼治疗二线厄洛替尼耐药晚期非小细胞肺癌的临床疗效和安全性
 4
 硫酸基转移酶1E1基因单核苷酸多态性联合吸烟与肺癌易感性的关系
 4
 培美曲塞治疗非小细胞肺癌无症状脑转移临床分析
 4
 上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用
 4
 首剂负荷量伊班膦酸钠治疗肺癌转移性骨痛的疗效和安全性分析
 4
 西妥昔单抗联合多西紫杉醇对EGFR-TKI获得性耐药的非小细胞肺癌细胞的作用
 4
 血管内皮生长因子C过表达或抑制表达对人小细胞肺癌NCI-H446细胞生物学行为的影响
 4
 重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的临床观察
 4
 多靶点受体酪氨酸激酶抑制剂联合化疗治疗晚期非小细胞肺癌的Meta分析
 3
 非小细胞肺癌CD44v6表达的免疫组化研究
 3
 ⅠB期非小细胞肺癌中K-ras的表达对辅助化疗预后的影响
 2
 2009年恶性肿瘤临床治疗新进展
 2
 34例卵巢透明细胞癌临床分析
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2